Profile of:
fabian-proft
Fabian Proft is a rheumatologist and senior researcher from Berlin, Germany. He received his medical degree at Munich University, where he also started his medical training and later on rheumatological specialisation. Since 2016 he has been working in the Department of Professor Denis Poddubnyy at Charité Berlin at a dedicated ASAS centre. His main research topics are axial spondyloarthritis and psoriatic arthritis with a strong focus on randomised controlled trials, digitalisation, outcome measures and imaging. He published numerous research articles, reviews and book chapters focusing on spondyloarthritis. Recently, one of his scientific focuses lies in early detection of spondyloarthritis using patient centred digital applications and the use of artificial intelligence for imaging assessment in patients with suspicion of axial spondyloarthritis. He is an active member of the Assessment of SpondyloArthritis International Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and he is part of the EMEUNET Peer-Mentoring subgroup. Furthermore, he served as chair of Young-GRAPPA (2021–2024) and served as one of the Young-ASAS Leaders (2021–2023).
Full name: fabian-proft
Current country: Germany
Membership level: Full
Type of membership: Member
Number of publications: 10
Bimekizumab-Treated Patients with Axial Spondyloarthritis Maintained Stringent Clinical Responses Over 3 Years: Phase 3 and Open-Label Extension Results (2026)
https://pubmed.ncbi.nlm.nih.gov/42967662/
Clinical and imaging characteristics of patients with axial psoriatic arthritis: Baseline findings from the GESPIC-axial-PsA cohort (2026)
https://pubmed.ncbi.nlm.nih.gov/42703355/
Impact of symptom duration on the short- and long-term efficacy of bimekizumab in axial spondyloarthritis: results up to 2 years (2026)
https://pubmed.ncbi.nlm.nih.gov/41555451/
Frequency of difficult-to-manage and treatment-refractory axial SpA: insights from the German RABBIT-SpA register using recent ASAS definitions (2026)
https://pubmed.ncbi.nlm.nih.gov/41335412/
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update (2023)
https://pubmed.ncbi.nlm.nih.gov/36270658/
HLA-B27 status and inflammatory MRI lesions of the sacroiliac joints: a post hoc analysis in patients without axial spondyloarthritis (2023)
https://pubmed.ncbi.nlm.nih.gov/37739448/
Spondyloarthritis, acute anterior uveitis, and Crohn’s disease have both shared and distinct gut microbiota (2023)
https://pubmed.ncbi.nlm.nih.gov/37471465/
Efficacy of tofacitinib in reduction of inflammation detected on MRI in patients with Psoriatic ArthritiS presenTing with axial involvement (PASTOR): protocol of a randomised, double-blind, placebo-controlled, multicentre trial (2021)
https://pubmed.ncbi.nlm.nih.gov/34785545/
Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial (2021)
https://pubmed.ncbi.nlm.nih.gov/33796155/
Diagnosing axial spondyloarthritis: estimation of the disease probability in patients with a priori different likelihoods of the diagnosis (2021)
https://pubmed.ncbi.nlm.nih.gov/33693503/